Agencies
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Agencies | Published : December 31, 2014 1:15 PM IST
Melbourne, Dec 31: A drug combination of artemisinin-naphthoquine should be considered for the treatment of children with malaria, suggests a study. The researchers studied malaria cases in Papua New Guinea. 'This regimen should be considered together with other currently available effective (artemisinin combination therapies) for treatment of uncomplicated malaria in Papua New Guinea and similar epidemiologic settings with transmission of multiple Plasmodium species,' said Tim Davis from University of Western Australia.
Malaria is a mosquito-borne parasitic disease that kills approximately 600,000 people every year. Several different parasite species cause malaria and in some settings, such as Papua New Guinea, two species, Plasmodium falciparum and Plasmodium vivax, are responsible for the majority of malaria infections. (Read: How is malaria treated?)
However, the two species respond differently to currently available anti-malarial drugs. The authors compared the current recommended therapy for malaria in children in Papua New Guinea, artemether-lumefantrine, with a different combination therapy, artemisinin-naphthoquine. Th trial study included 186 children with Plasmodium falciparum infections and 47 children with Plasmodium vivax infections. The researchers found that artemisinin-naphthoquine was no worse than artemether-lumefantrine for treating Plasmodium falciparum, but was more effective for treating Plasmodium vivax. The study appeared in the journal PLOS Medicine. (Read: Ranbaxy to launch anti-malaria drug Synriam 7
African nations by January 2015)
Source: IANS
Photo source: Getty images
For more articles on malaria, visit our malaria section. For daily free health tips, sign up for our newsletter.
